FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Surg / Toll-like receptor activation of equine mesenchymal stromal ...
Veterinary surgery : VS2021; 50(4); 858-871; doi: 10.1111/vsu.13628

Toll-like receptor activation of equine mesenchymal stromal cells to enhance antibacterial activity and immunomodulatory cytokine secretion.

Abstract: To evaluate effects of Toll-like and nucleotide-binding oligomerization domain (NOD)-like receptor (TLR, NLR) ligand stimulation of equine mesenchymal stromal cells (MSCs) on antibacterial and immunomodulatory properties in vitro. Methods: Controlled laboratory study. Methods: Equine bone-marrow-derived MSCs (three horses). Methods: MSCs were stimulated with TLR (polyinosinic:polycytidylic acid [pIC] and lipopolysaccharide [LPS]) and NLR agonists (γ-d-Glu-mDAP [IE-DAP]) for 2 h, and plated at 1 × 105 cells/well 24 h. MSC-conditioned media (MSC-CM) were collected and assessed for antimicrobial peptide cathelicidin/LL-37 production, bactericidal action against multidrug-resistant planktonic and biofilm Staphylococcus aureus and neutrophil phagocytosis. Bacterial growth was measured by plating bacteria and counting viable colonies, reading culture absorbance, and live-dead staining with confocal microscopy imaging. Following initial comparison of activating stimuli, TLR3-agonist pIC protocols (cell density during activation and plating, culture time, %serum) were further optimized for bactericidal activity and secretion of interleukin-8 (IL-8), monocyte-chemoattractant-protein (MCP-1), and cathelicidin/LL37. Results: MSCs stimulation with pIC (p = .004) and IE-DAP (p = .03) promoted increased bactericidal activity, evidenced by reduced viable planktonic colony counts. PIC stimulation (2 × 106 cells/ml, 2 h, 10 μg/ml) further suppressed biofilm formation (p = .001), enhanced neutrophil bacterial phagocytosis (p = .009), increased MCP-1 secretion (p < .0001), and enhanced cathelicidin/LL-37 production, which was apparent when serum concentration in media was reduced to 1% (p = .01) and 2.5% (p = .05). Conclusions: TLR-3 pIC MSCs activation was most effective to enhance antibacterial and cytokine responses, which were affected by serum reduction. Conclusions: In vitro TLR-3 activation of equine MSCs tested here may be a strategy to improve antibacterial properties of MSCs to treat antibiotic-resistant infections.
© 2021 American College of Veterinary Surgeons.
Get Full Text
Publication Date: 2021-04-02 PubMed ID: 33797775DOI: 10.1111/vsu.13628Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the impact of stimulating Toll-like and nucleotide-binding oligomerization domain-like receptors in equine mesenchymal stromal cells on their antibacterial properties and ability to immunomodulate. Specific protocols involving different stimulation, cell density, and culture time were tested. The findings suggest that TLR-3 stimulation could be an effective way to enhance their antibacterial properties, which could be beneficial for treating antibiotic-resistant infections.

Purpose and Methodology

  • The focus of the study was to look into the effects of stimulating Toll-like and nucleotide-binding oligomerization domain-like receptor (TLR, NLR) in equine mesenchymal stromal cells (MSCs).
  • The purpose was to observe any changes in the cells’ antibacterial and immunomodulatory properties.
  • The researchers conducted the study in a controlled laboratory environment using MSCs derived from the bone marrow of three horses.
  • The stimulation process involved using TLR (polyinosinic:polycytidylic acid [pIC] and lipopolysaccharide [LPS]) and NLR agonists (γ-d-Glu-mDAP [IE-DAP]).

Experimental Design and Procedures

  • The MSCs were stimulated for 2 hours and placed at 1 x 10 cells/well for 24 hours.
  • The researchers then collected MSC conditioned media (MSC-CM) and evaluated them for the production of antimicrobial peptide cathelicidin/LL-37, their action against multidrug-resistant Staphylococcus aureus and neutrophil phagocytosis.
  • Bacterial growth was measured by counting viable colonies, assessing culture absorbance, and live-dead staining with confocal microscopy imaging.

Results and Further Optimization

  • Post initial comparison, TLR3-agonist pIC protocols were further optimized for bactericidal activity and secretion of interleukin-8 (IL-8), monocyte-chemoattractant-protein (MCP-1), and cathelicidin/LL37.
  • The results showed that the stimulation of MSCs with pIC and IE-DAP promoted an increase in bactericidal activity, as noticeable with reduced viable colony counts.
  • pIC stimulation also suppressed biofilm formation, enhanced neutrophil bacterial phagocytosis, increased MCP-1 secretion, and enhanced cathelicidin/LL-37 production.
  • The effects were more pronounced when the serum concentration was further reduced to 1% and 2.5%.

Conclusions

  • The study concluded that TLR-3 pIC stimulation was the most effective way to enhance antibacterial and cytokine responses in the MSCs.
  • The effects were even more apparent with serum reduction.
  • This suggests that in vitro TLR-3 activation of equine MSCs could be used as a strategy to improve the antibacterial properties of these cells to combat antibiotic-resistant infections.

Cite This Article

APA
Pezzanite LM, Chow L, Johnson V, Griffenhagen GM, Goodrich L, Dow S. (2021). Toll-like receptor activation of equine mesenchymal stromal cells to enhance antibacterial activity and immunomodulatory cytokine secretion. Vet Surg, 50(4), 858-871. https://doi.org/10.1111/vsu.13628

Publication

Veterinary surgery : VS
ISSN: 1532-950X
NlmUniqueID: 8113214
Country: United States
Language: English
Volume: 50
Issue: 4
Pages: 858-871

Researcher Affiliations

Pezzanite, Lynn M
  • Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Colorado, USA.
Chow, Lyndah
  • Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Colorado, USA.
Johnson, Valerie
  • Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Colorado, USA.
Griffenhagen, Gregg M
  • Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Colorado, USA.
Goodrich, Laurie
  • Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Colorado, USA.
Dow, Steven
  • Department of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Colorado, USA.

MeSH Terms

  • Animals
  • Antimicrobial Cationic Peptides / biosynthesis
  • Biofilms
  • Cytokines / biosynthesis
  • Drug Resistance, Multiple, Bacterial / immunology
  • Horses / immunology
  • Immunomodulation / genetics
  • Mesenchymal Stem Cells / immunology
  • Neutrophils / drug effects
  • Phagocytosis / drug effects
  • Staphylococcus aureus / physiology
  • Toll-Like Receptors / metabolism
  • Cathelicidins

Grant Funding

  • ACVS Zoetis Dual Training Grant
  • Carolyn Quan and Porter Bennett
  • CCTSI NIH/NCATS CTSA TL1TR002533
  • NIH 5T32OD010437-19
  • Shipley Foundation
  • Verdad Foundation

References

This article includes 92 references
  1. Vergidis P, Schmidt-Malan SM, Mandrekar JN, Steckelberg JM, Patel R. Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant Staphylococcus aureus osteomyelitis.. J Infect 2015;70:609-615.
  2. Moriarty TF, Kuehl R, Coenye T. Orthopaedic device related infection: current and future interventions for improved prevention and treatment.. EFORT Open Rev 2017;1(4):89-99.
  3. Pellerin JL, Bourdeau P, Sebbag H, Person JM. Epidemiosurveillance of antimicrobial compound resistance of Staphylococcus intermedium clinical isolates from canine pyodermas.. Comp Immunol Microbiol Inf Dis 1998;21(2):115-133.
  4. Amato-Gauci A, Ammon A. The First European Communicable Disease Epidemiological Report.. Paper presented at: European Centre for Disease Prevention and Control; June 7, 2007; Stockholm, Sweden.
  5. Loncaric I, Kunzel F, Licka T, Simhofer H, Spergser J, Rosengarten R. Identification and characterization of methicillin-resistant Staphylococcus aureus (MRSA) from Austrian companion animals and horses.. Vet Microbiol 2014;168(2-4):381-387.
  6. Theelen MJ, Wilson WD, Edman JM, Magdesian KG, Kass PH. Temporal trends in prevalence of bacteria isolated from foals with sepsis: 1979-2010.. Equine Vet J 2014;46(2):169-173.
  7. Mallardo K, Nizza S, Fiorito F, Pagnini U, de Martino L. A comparative evaluation of methicillin-resistant staphylococci isolated from harness racing-horses, breeding mares and riding-horses in Italy.. Asian Pac J Trop Biomed 2013;3(3):169-173.
  8. Singh BR. Prevalence of vancomycin resistance and multiple drug resistance in enterococci in equids in North India.. J Infect Dev Ctries 2009;3(7):498-503.
  9. van den Eede A, Martens A, Linpinska U. High occurrence of methicillin-resistant Staphylococcus aureus ST398 in equine nasal samples.. Vet Microbiol 2009;133(1-2):138-144.
  10. van den Eede A, Hermans K, van den Abeele A. Methicillin-resistant Staphylococcus aureus (MRSA) on the skin of long-term hospitalized horses.. Vet J 2012;193(2):408-411.
  11. Herdan CL, Acke E, Dicken M. Multi-drug resistant Enterococcus spp. as a cause of non-responsive septic synovitis in three horses.. N Z Vet J 2012;60(5):297-304.
  12. Ahern BJ, Richardson DW, Boston RC, Schaer TP. Orthopedic infections in equine long bone fractures and arthrodeses treated by internal fixation: 192 cases (1990-2006).. Vet Surg 2010;39(5):588-593.
  13. MacDonald DG, Morley PS, Bailey JV, Barber SM, Fretz PB. An examination of the occurrence of surgical wound infection following routine orthopedic surgery (1981-1990).. Equine Vet J 1994;26(4):323-326.
  14. James FM, Richardson DW. Minimally invasive plate fixation of lower limb injury in horses: 32 cases (1999-2003).. Equine Vet J 2006;38(3):246-251.
  15. Levine DG, Richardson DW. Clinical use of the locking compression plate (LCP) in horses: a retrospective study of 31 cases (2004-2006).. Equine Vet J 2007;39(5):401-406.
  16. Curtiss AL, Stefanovski D, Richardson DW. Surgical site infection associated with equine orthopedic internal fixation: 155 cases (2008-2016).. Vet Surg 2019;48(5):685-693.
  17. Rightmire E, Zurakowski D, Vrahas M. Acute infections after fracture repair: management with hardware in place.. Clin Orthop Relat Res 2008;466(2):466-472.
  18. Patzakis MJ, Wilkins J. Factors influencing infection rate in open fracture wounds.. Clin Orthop Relat Res 1989;243:36-40.
  19. Boxma H, Broekhuizen T, Patka P, Oosting H. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch trauma trial.. Lancet 1996;347(9009):1133-1137.
  20. Tetetrycz D, Ferry T, Lew D. Outcome of orthopedic implant infections due to different staphylococci.. Int J Infect Dis 2010;14(10):e913-e9188.
  21. Beswick AD, Elvers KT, Smith AJ, Gooberman-Hill R, Lovering A, Blom AW. What is the evidence base to guide surgical treatment of infected hip prostheses? Systematic review of longitudinal studies in unselected patients.. BMC Med 2012;10:18.
    doi: 10.1186/1741-7015-10-18google scholar: lookup
  22. Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection.. Lancet 2016;387(10016):386-394.
  23. Tsaras G, Osmon DR, Mabry T. Incidence, secular trends, and outcomes of prosthetic joint infection: a population-based study, olmsted county, Minnesota, 1969-2007.. Infect Control Hosp Epidemiol 2012;33(12):1207-1212.
  24. Poultsides LA, Liaropoulos LL, Malizos KN. The socioeconomic impact of musculoskeletal infections.. J Bone Joint Surg Am 2010;92(11):e13.
    doi: 10.2106/jbjs.i.01131google scholar: lookup
  25. Nauth A, Lee M, Gardner MJ. Principles of nonunion management: state of the art.. J Orthop Trauma 2018;32:S52-S57.
  26. Harman RM, Yang S, He MK, van de Walle GR. Antimicrobial peptides secreted by equine mesenchymal stromal cells inhibit the growth of bacteria commonly found in skin wounds.. Stem Cell Res Ther 2017;8(1):157.
  27. Gilbertie JM, Schaer TP, Schubert EG. Platelet-rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro.. J Orthop Res 2020;38(6):1365-1374.
  28. Cortés-Araya Y, Amilon K, Rink BE. Comparison of antibacterial and immunological properties of mesenchymal stem/stromal cells from equine bone marrow, endometrium, and adipose tissue.. Stem Cells Dev 2018;27(21):1518-1525.
  29. Wang M, Tang T. Surface treatment strategies to combat implant-related infection from the beginning.. J Orthop Translat 2019;17:42-54.
  30. Zhang L, Gaozhi J, Tang M. Simultaneous enhancement of anti-corrosion, biocompatibility, and antimicrobial activities by hierarchically-structured brushite/Ag3PO4-coated Mg-based scaffolds.. Mater Sci Eng C Mater Biol Appl 2020;111:110779.
    doi: 10.1016/j.msec.2020.110779google scholar: lookup
  31. Li Y, Li G, Sha X. An intelligent vancomycin release system for preventing surgical site infections of bone tissues.. Biomater Sci 2020;8(11):3202-3211.
  32. Asano K, Yoshimura S, Nakane A. Adipose tissue-derived mesenchymal stem cells attenuate staphylococcal enterotoxin A-induced toxic shock.. Infect Immun 2015;83(9):3490-3496.
  33. Brandau S, Jakob M, Bruderek K. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes.. PLoS One 2014;9(9):e106903.
    doi: 10.1371/journal.pone.0106903google scholar: lookup
  34. Chao YH, Wu HP, Wu KH. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.. PLoS One 2014;9(10):e110338.
    doi: 10.1371/journal.pone.0110338google scholar: lookup
  35. de Witte S, Luke F, Parraga JMS. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells.. Stem Cells 2018;36(4):602-615.
  36. Edmiston CE Jr, McBain AJ, Roberts C, Leaper D. Clinical and microbiological aspects of biofilm associated surgical site infections.. Adv Exp Med Biol 2015;830:47-67.
  37. Eggenhofer E, Hoogduijn MJ. Mesenchymal stem cell-educated macrophages.. Transplant Res 2012;1(1):12.
  38. Krasnodembskaya A, Song Y, Fang X. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.. Stem Cells 2010;28(12):2229-2238.
  39. Krasnodembskaya A, Samarani G, Song Y. Mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes.. Am J Physiol Lung Cell Mol Physiol 2012;302(10):1003-1013.
  40. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system.. Nat Rev Immunol 2012;12(5):383-396.
  41. Mei SH, Haitsma JJ, dos Santos CC. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.. Am J Respir Crit Care Med 2015;182(8):1047-1057.
  42. Mezey É, Nemeth K. Mesenchymal stem cells and infectious diseases: smarter than drugs.. Immunol Lett 2015;168(2):208-214.
  43. Monneret G. Mesenchymal stem cells: another anti-inflammatory treatment for sepsis?. Nat Med 2009;15(6):601-602.
  44. Németh K, Leelahavanichkul A, Yuen PST. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.. Nat Med 2009;15(1):42-49.
  45. Kim J, Hernatti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.. Exp Hematol 2009;37(12):1445-1453.
  46. Lee JW, Gupta N, Serikov V, Matthay MA. Potential application of mesenchymal stem cells in acute lung injury.. Expert Opin Biol Ther 2009;9(10):1259-1270.
  47. Cruz FF, Weiss DJ, Rocco PRM. Prospects and progress in cell therapy for acute respiratory distress syndrome.. Expert Opin Biol Ther 2016;16(11):1353-1360.
  48. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells.. Trends Mol Med 2012;18(2):128-134.
  49. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by toll- like receptors: implications on therapeutic potential.. Mediators Inflamm 2010;2010:1-9.
    doi: 10.1155/2010/865601google scholar: lookup
  50. DelaRosa O, Dalemans W, Lombardo E. Toll-like receptors as modulators of mesenchymal stem cells.. Front Immunol 2012;3:1-8.
    doi: 10.3389/fimmu.2012.00182google scholar: lookup
  51. Johnson V, Webb T, Dow S. Activated mesenchymal stem cells amplify antibiotic activity against chronic Staphylococcus aureus infection.. J Immunol 2013;190(1s):11.
  52. Johnson V, Norman A, Norman A. Activated mesenchymal stem cells interact with antibiotics and host innate immune responses to control chronic bacterial infections.. Sci Rep 2017;7(1):9575.
  53. Won Kang J, Kang K-S, Koo HC, Park JR, Choi EW, Park YH. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells.. Stem Cells Dev 2008;17(4):681-693.
  54. Chen X, Zhang ZY, Zhou H, Zhou G-W. Characterization of mesenchymal stem cells under the stimulation of toll-like receptor agonists.. Dev Growth Differ 2014;56(3):233-244.
  55. Sangiorgi B, Panepucci RA. Modulation of Immunoregulatory properties of mesenchymal stromal cells by toll-like receptors: potential applications on GVHD.. Stem Cells Int 2016;2016:1-10.
    doi: 10.1155/2016/9434250google scholar: lookup
  56. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.. Stem Cells 2008;26(1):99-107.
  57. Sung PH, Chiang HJ, Chen CH. Combined therapy with adipose-derived mesenchymal stem cells and ciprofloxacin against acute urogenital organ damage in rat sepsis syndrome induced by intrapelvic injection of cecal bacteria.. Stem Cells Transl Med 2016;5(6):782-792.
  58. Sutton MT, Fletcher D, Ghosh SK. Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis, infection and treatment.. Stem Cells Int 2016;2016:1-12.
    doi: 10.1155/2016/5303048google scholar: lookup
  59. Zou J-P, Huang S, Peng Y. Mesenchymal stem cells/multipotent mesenchymal stromal cells (MSCs): potential role in healing cutaneous chronic wounds.. Int J Low Extrem Wounds 2012;11(4):244-253.
  60. Radcliffe CH, Flaminio MJB, Fortier LA. Temporal analysis of equine bone marrow aspirate during establishment of putative mesenchymal progenitor cell populations.. Stem Cells Dev 2010;19(2):269-282.
  61. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJB, Fortier LA. Equine bone marrow derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014;5(1):13.
  62. Esteves CL, Sheldrake TA, Mesquita SP. Isolation and characterization of equine native MSC populations.. Stem Cell Res Ther 2017;8(1):80.
  63. Dominici M, le Blanc K, Mueller I. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.. Cytotherapy 2006;8(4):315-317.
  64. Chow L, Johnson V, Impastato R, Coy J, Strumpf A, Dow S. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells.. Stem Cells Transl Med 2020;9(2):235-249.
  65. Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L. Mesenchymal stromal cells and toll-like receptor priming: a critical review.. Immune Netw 2017;17(2):89-102.
  66. Rasband WS. Image J, U.S. (1997-2018).. Bethesda, Maryland: National Institutes of Health; 2018.
  67. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis.. Nat Methods 2012;9(7):671-675.
  68. Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ.. Biophotonics Int 2004;11(7):36-42.
  69. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4.. J Stat Softw 2015;67(1):1-48.
  70. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models.. J Stat Softw 2017;82(13):1-26.
  71. Lenth R. emmeans: estimated Marginal Means, aka Least-Squares Means. R package version 1.4.7.. 2020.
  72. R Core Team. R: A Language and Environment for Statistical Computing.. Vienna, Austria: R Foundation for Statistical Computing; 2020.
  73. Yuan Y, Lin S, Guo N. Marrow mesenchymal stromal cells reduce methicillin-resistant Staphylococcus aureus infection in rat models.. Cytotherapy 2014;16(1):56-63.
  74. Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figueroa FE, Khoury M. Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis.. Stem Cell Res Ther 2015;6:199.
  75. Gupta N, Krasnodembskaya A, Kapetanaki M. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia.. Thorax 2012;67(6):533-539.
  76. Sivertson A, Isaksson J, Leiros H-KS, Svenson J-S, Svendsen J-S, Brandsdal BO. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin.. BMC Struct Biol 2014;14:4.
  77. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities.. Cell Stem Cell 2018;22(6):824-833.
  78. Nuschke A. Activity of mesenchymal stem cells in therapies for chronic skin wound healing.. Organogenesis 2014;10(1):29-37.
  79. Kanji S, Das H. Advances of stem cell therapeutics in cutaneous wound healing and regeneration.. Mediators Inflamm 2017;2017:1-14.
    doi: 10.1155/2017/5217967google scholar: lookup
  80. Kuznetsov SA, Mankani MH, Robey PG. Effect of serum on human bone marrow stromal cells: ex vivo expansion and in vivo bone formation.. Transplantation 2000;70(12):1780-1787.
  81. Aldahmash A, Haack-Sorensen M, Al-Nbaheen M, Harkness L, Abdallah B, Kassem M. Human serum is as efficient as fetal bovine serum in supporting proliferation and differentiation of human multipotent stromal (mesenchymal) stem cells in vitro and in vivo.. Stem Cell Rev Rep 2011;7(4):860-868.
  82. Popov A, Scotchford C, Grant D, Sottile V. Impact of serum source on human mesenchymal stem cell osteogenic differentiation in culture.. Int J Mol Sci 2019;20(20):5051.
  83. Pérez-Ilzarbe M, Diez-Campelo M, Aranda P. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy.. Transfusion 2009;49(9):1901-1910.
  84. Escobedo-Lucea C, Bellver C, Gandia C. A xenogenic-free protocol for isolation and expansion of human adipose stem cells for clinical uses.. PLoS One 2013;8(7):e67870.
  85. Drach G, Maret A, Richard MF, Barbu E. Transfer and induction of delayed hypersensitivity to methylated bovine serum albumin in the absence of adjuvant.. C R Acad Sci Hebd Seances Acad Sci D 1977;284:2435-2437.
  86. World Health Organization. Medicinal and other products and human and animal transmissible spongiform encephalopathies: memorandum from a WHO meeting.. Bull World Health Organ 1997;75:505-513.
  87. Karnieli O, Friedner OM, Allickson JG. A consensus introduction to serum replacements and serum-free media for cellular therapies.. Cytotherapy 2017;19:155-169.
  88. European Commission. Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Enceaphlopathy Agents Via Human and Veterinary Medicinal Products (EMA/410/01 Rev.3).. Official Journal of the European Union Brussels; 2011.
  89. European Medicines Agency. Guideline on Human Cell-Based Medicinal Products.. London, UK: European Medicines Agency; 2008.
  90. European Medicines Agency. Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products 2013.. London: European Medicines Agency; 2013.
  91. Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective.. Cell Stem Cell 2014;14:141-145.
  92. Pezzanite L, Chow L, Griffenhagen G, Dow S, Goodrich L. Impact of three different serum sources on functional properties of equine mesenchymal stromal cells.. Front Vet Sci .
    doi: 10.3389/fvets.2021.634064google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.